Spesolimab: A Novel Interleukin-36 Receptor Monoclonal Antibody for the Treatment of Generalized Pustular Psoriasis
DOI:
https://doi.org/10.22270/ajprd.v11i3.1400Abstract
Psoriasis is an autoimmune condition affecting multiple organs in the body (joints, cardiovascular, and central nervous system), especially the skin. Psoriasis is characterized by inflammation, epidermal hyperproliferation, and aberrant epidermal differentiation. One of the uncommon types of psoriasis is generalized pustular psoriasis (GPP) which is uncommon and associated with increased severity and systemic complications. Early diagnosis is the crucial step in treating GPP to manage its life-threatening complications. Pathogenesis of GPP is still under research. The treatment of GPP aims for symptomatic relief, to remove skin lesions, and to provide supportive care. However, there are no specific guidelines or therapeutic options and it mostly depends on the clinician's opinion that often follows for plaque psoriasis. Accumulating data revealed that the interleukin-36 (IL-36) pathway plays a major role and signaling to favor the pro-inflammatory activity, which is critical in the pathogenesis of GPP, thus starting the maneuver of development of targeted biological therapies for the disease. This article reviews the role of IL-36 in the pathogenesis of GPP and appraisals the evidence of safety, tolerability, potential,and superior efficacy of spesolimab, a novel IL-36 monoclonal antibody developed by Boehringer Ingelheim. It is recently approved for the treatment of GPP fares in adults in the US, the European Union, and Japan. Spesolimab is a first-in-class medication that changed a paradigm shift in the management of GPP based on evidence-based targeted biologic therapy and clinical success for this distinctive type of psoriasis disease.
Downloads
References
Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79-82.
Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-3.
Bachelez H. Pustular Psoriasis: The Dawn of a New Era. Acta Derm Venereol. 2020;100(3):adv00034.
Zheng M, Jullien D, Eyerich K. The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5-12.
Bernardo D, Thaçi D, Torres T. Spesolimab for the Treatment of Generalized Pustular Psoriasis. Drugs. 2024;84(1):45-58.
Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P, Puig L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatol Ther (Heidelb). 2023;13(3):673-88.
Sugiura K. Role of Interleukin 36 in Generalised Pustular Psoriasis and Beyond. Dermatol Ther (Heidelb). 2022;12(2):315-28.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13-9.
Puig L, Choon SE, Gottlieb AB, Marrakchi S, Prinz JC, Romiti R, Tada Y, von Bredow D, Gooderham M. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737-52.
Choon SE, Lebwohl MG, Turki H, Zheng M, Burden AD, Li L, Quaresma M, Thoma C, Bachelez H. Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares. Dermatology. 2023;239(3):345-54.
Reynolds KA, Pithadia DJ, Lee EB, Clarey D, Liao W, Wu JJ. Generalized Pustular Psoriasis: A Review of the Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment. Cutis. 2022;110(2 Suppl):19-25.
Bukhari T, Markovina M, Abduelmula A, Rankin BD, Vender R, Yeung J, Devani AR, Prajapati VH. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients. Skin Therapy Lett. 2024;29(1):1-4.
Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12):1746.
Krueger J, Puig L, Thaçi D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51-64. s
Hsieh CY, Tsai TF. Clinical advances in biological therapy for generalized pustular psoriasis: a review. Expert Opin Biol Ther. 2024;24(1-2):37-50.
Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021;11(6):1917-29.
Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-44.
Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1015-27.
Elias M, Zhao S, Le HT, Wang J, Neurath MF, Neufert C, Fiocchi C, Rieder F. IL-36 in chronic inflammation and fibrosis - bridging the gap? J Clin Invest. 2021;131(2):e144336.
Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. Int J Mol Sci. 2019;20(13):3318.
Fukaura R, Akiyama M. Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs. 2023;37(3):279-93.
Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022;156:155897.
Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ, Doti N, Pagnanelli G, Gubinelli E, Mazzanti C, Cavani A, Ruvo M, Dinarello CA, Albanesi C, Madonna S. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018;9(11):1104.
Murrieta-Coxca JM, Rodríguez-Martínez S, Cancino-Diaz ME, Markert UR, Favaro RR, Morales-Prieto DM. IL-36 Cytokines: Regulators of Inflammatory Responses and Their Emerging Role in Immunology of Reproduction. Int J Mol Sci. 2019;20(7):1649.
Yuan ZC, Xu WD, Liu XY, Liu XY, Huang AF, Su LC. Biology of IL-36 Signaling and Its Role in Systemic Inflammatory Diseases. Front Immunol. 2019;10:2532.
Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Exp Dermatol. 2023;32(8):1204-18.
Trai NN, Van Em D, Van BT, My LH, Van Tro C, Hao NT, Vu HA, Tram DB, Van Thuong N, Doanh LH. Correlation of IL36RN and CARD14 mutations with clinical manifestations and laboratory findings in patients with generalised pustular psoriasis. Indian J Dermatol Venereol Leprol. 2023;89(3):378-84.
Palaniappan V, Gopinath H, Murthy AB, Radhakrishnan S, Karthikeyan K. Spesolimab: a comprehensive review on the anti-IL-36 receptor antibody in dermatology. Int J Dermatol. 2024;63(1):88-93.
Samotij D, Szczęch J, Reich A. Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity. Int J Mol Sci. 2021;22(16):9048.
Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81.
Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47(6):118.
Burden AD. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Rev Clin Immunol. 2023;19(5):473-81.
Blair HA. Spesolimab: First Approval. Drugs. 2022;82(17):1681-86.
Rega F, Trovato F, Bortone G, Pellacani G, Richetta AG, Dattola A. Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date. Psoriasis (Auckl). 2024;14:23-27.
Elewski BE, Lebwohl MG, Anadkat MJ, Barker J, Ghoreschi K, Imafuku S, Mrowietz U, Li L, Quaresma M, Thoma C, Bachelez H. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023;89(1):36-44.
Morita A, Choon SE, Bachelez H, Anadkat MJ, Marrakchi S, Zheng M, Tsai TF, Turki H, Hua H, Rajeswari S, Thoma C, Burden AD. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis. Dermatol Ther (Heidelb). 2023;13(1):347-59.
Wen P, Liu C, Wang T, Jiang X, Wang P, Wang S. Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report. Front Immunol. 2024;15:1338285.
Hawkes JE, Visvanathan S, Krueger JG. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Front Immunol. 2023 21;14:1292941.
Baum P, Visvanathan S, Garcet S, Roy J, Schmid R, Bossert S, Lang B, Bachelez H, Bissonnette R, Thoma C, Krueger JG. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402-12.
Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021;11(2):571-85.
Joseph D, Thoma C, Haeufel T, Li X. Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies. Clin Pharmacokinet. 2022;61(12):1771-87.
SPEVIGO® approved for expanded indications in China and the US. Available: https://www.boehringer-ingelheim.com/us/human-health/skin-and-inflammatory-diseases/gpp/spevigo-approved-expanded-indications-china-and-us. Accessed on 16 April 2024.
Spesolimab. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf. Accessed 16 April 2024.
Yang C, Wang Y, Li R, Tu P, Wang R. Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab. J Dermatolog Treat. 2024;35(1):2334791.
Guénin SH, Khattri S, Lebwohl MG. Spesolimab use in treatment of pyoderma gangrenosum. JAAD Case Rep. 2023;34:18-22.
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa. Available: https://clinicaltrials.gov/study/NCT04762277. Accessed on 16 April 2024.
A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial. Available: https://clinicaltrials.gov/study/NCT04876391. Accessed on 16 April 2024.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Rupali Pachusing Sable, Anuja G Gawai, Vrunda J Rajput, Subodh A Urkunde, Sandeep C Atram
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 